Table 2.
Antinuclear and antiphospholipid autoantibodies in patients with COVID-19.
| Mild (n = 59) | Severe (n = 98) | Total (n = 157) | p value | |
|---|---|---|---|---|
| ANA positivity—n (%) | 15 (33.3%) | 16 (26.7%) | 31 (29.5%) | 0.459 |
| Missing values | 14 | 38 | 52 | |
| aPL positive—n (%) | 26 (44.1%) | 60 (61.2%) | 86 (54.8%) | 0.036 |
| aCL IgG | 4 (6.8%) | 37 (37.8%) | 41 (26.1%) | < 0.001 |
| aCL IgM | 6 (10.2%) | 7 (7.1%) | 13 (8.3%) | 0.505 |
| aCL IgG IgA | 0 (0.0%) | 2 (2.1%) | 2 (1.3%) | 0.263 |
| Missing values | 1 | 4 | 5 | |
| aB2GPI IgG | 2 (3.4%) | 4 (4.1%) | 6 (3.8%) | 0.827 |
| aB2GPI IgM | 4 (6.8%) | 6 (6.1%) | 10 (6.4%) | 0.870 |
| aB2GPI IgA | 10 (17.2%) | 12 (12.8%) | 22 (14.5%) | 0.446 |
| Missing values | 1 | 4 | 5 | |
| aPE IgG | 7 (11.9%) | 18 (19.1%) | 25 (16.3%) | 0.236 |
| Missing values | 0 | 4 | 4 | |
| aPE IgM | 2 (3.4%) | 4 (4.3%) | 6 (3.9%) | 0.788 |
| Missing values | 0 | 4 | 4 | |
| aPE IgA | 1 (7.7%) | 0 (0.0%) | 1 (2.3%) | 0.124 |
| Missing values | 46 | 68 | 114 | |
| aPT IgG | 0 (0.0%) | 1 (1.1%) | 1 (0.7%) | 0.445 |
| Missing values | 8 | 10 | 18 | |
| aPT IgM | 5 (9.8%) | 17 (19.3%) | 22 (15.8%) | 0.139 |
| Missing values | 8 | 10 | 18 |
aPL antiphospholipid, aCL anti-cardiolipin, aB2GPI anti-beta-2 glycoprotein I, aPE anti-phosphatidylethanolamine, aPT anti-prothombin autoantibodies, ANA antinuclear autoantibodies.